Your Messages Inbox
Your Article Summary
See Latest ArticlesMediGene: USPTO Grants Extension of a Patent on Veregen
MediGene, 04/08/09
The U.S. Patent and Trademark Office has granted an extension of patent no. US 5,795,911 for Veregen by 1,300 days, i.e. approx. 3.5 years. This means that the US patent, originally granted until April 2017, will now lapse in October 2020. This basic patent protects the treatment of genital warts with catechins from green tea. It is listed in the U.S. Food and Drug Administration's Orange Book, the approved drug list, under VEREGEN, SINECATECHINS, OINTMENT, TOPICAL 15%.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
US FDA approves SEROQUEL XR for add-on treatment of Major Depressive Disorder
AstraZeneca, 12/07/09
FDA Approves Initiation of Clinical Studies in the U.S. for T2000, Taros Proprietary Non-Sedating Barbiturate Compound
Taro Pharmaceuticals USA, 12/07/09
Article Search
Sponsor